Akebia Therapeutics (AKBA) Earnings Date, Estimates & Call Transcripts $1.37 -0.03 (-2.14%) (As of 09/17/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 13EstimatedActual EPS (Aug. 8) -$0.04 Beat By $0.02 Consensus EPS (Aug. 8) -$0.06 Conference Call TranscriptConference Call AudioEarnings Press Release Get Akebia Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for AKBA and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueAKBA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AKBA Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlace“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.Click here to see his official warning. Akebia Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.09)($0.09)($0.09)Q2 20241($0.07)($0.07)($0.07)Q3 20241($0.06)($0.06)($0.06)Q4 20241($0.04)($0.04)($0.04)FY 20244($0.26)($0.26)($0.26)Q1 20251($0.14)($0.14)($0.14)Q2 20251($0.13)($0.13)($0.13)Q3 20251($0.11)($0.11)($0.11)Q4 20251($0.05)($0.05)($0.05)FY 20254($0.43)($0.43)($0.43)AKBA Earnings Date and InformationAkebia Therapeutics last issued its earnings results on August 8th, 2024. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business had revenue of $43.65 million for the quarter, compared to the consensus estimate of $45.61 million. Akebia Therapeutics has generated ($0.23) earnings per share over the last year (($0.23) diluted earnings per share). Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.19) to ($0.17) per share. Akebia Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off prior year's report dates.Read More Akebia Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/13/2024(Estimated)------- 8/8/2024Q2 2024($0.06)($0.04)+$0.02($0.04)$45.61 million$43.65 million 5/9/2024Q1 2024($0.09)($0.09)-($0.09)$41.13 million$32.61 million 3/14/2024Q4 2023($0.04)($0.04)--$55.64 million$56.20 million 11/8/2023Q3 2023($0.09)($0.08)+$0.01($0.08)$48.19 million$42.05 million 8/25/2023Q2 2023($0.03)($0.06)($0.03)($0.06)$59.10 million$56.38 million 5/8/2023Q1 2023($0.15)($0.14)+$0.01($0.14)$46.69 million$40.13 million Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/9/2023Q4 2022($0.14)($0.04)+$0.10($0.04)$48.35 million$55.18 million 11/3/2022Q3 2022($0.15)($0.28)($0.13)($0.28)$47.17 million$48.96 million 8/4/2022Q2 2022($0.31)$0.23+$0.54$0.31$49.10 million$126.76 million 5/9/2022Q1 2022($0.27)($0.35)($0.08)($0.35)$44.37 million$61.70 million 3/1/2022Q4 2021($0.33)($0.40)($0.07)($0.40)$48.22 million$59.61 million 11/4/2021Q3 2021($0.32)($0.34)($0.02)($0.34)$50.09 million$48.76 million 8/4/2021Q2 2021($0.30)($0.51)($0.21)($0.51)$60.08 million$52.91 million 5/9/2021Q1 2021($0.33)($0.45)($0.12)($0.45)$43.80 million$52.30 million 2/24/2021Q4 2020($0.40)($0.60)($0.20)($0.60)$47.86 million$56.70 million 11/10/2020Q3 2020($0.17)($0.42)($0.25)($0.42)$76.12 million$59.99 million 8/10/2020Q2 2020($0.46)($0.44)+$0.02$0.40$76.24 million$90.14 million5/5/2020Q1 2020($0.62)($0.47)+$0.15($0.47)$77.54 million$88.48 million 3/10/2020Q4 2019($0.47)($0.79)($0.32)($0.43)$95.40 million$69.56 million 11/12/2019Q3 2019($0.37)($0.4592)($0.0892)($0.10)$93.94 million$91.98 million Akebia Therapeutics Earnings - Frequently Asked Questions When is Akebia Therapeutics's earnings date? Akebia Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off last year's report dates. Learn more on AKBA's earnings history. Did Akebia Therapeutics beat their earnings estimates last quarter? In the previous quarter, Akebia Therapeutics (NASDAQ:AKBA) reported ($0.04) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.06) by $0.02. Learn more on analysts' earnings estimate vs. AKBA's actual earnings. How can I listen to Akebia Therapeutics's earnings conference call? The conference call for Akebia Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Akebia Therapeutics's conference call transcript? The conference call transcript for Akebia Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded annual revenue of $174.50 million. How much profit does Akebia Therapeutics generate each year? Akebia Therapeutics (NASDAQ:AKBA) has a recorded net income of -$51.92 million. AKBA has generated -$0.23 earnings per share over the last four quarters. What is Akebia Therapeutics's EPS forecast for next year? Akebia Therapeutics's earnings are expected to grow from ($0.19) per share to ($0.17) per share in the next year. More Earnings Resources from MarketBeat Related Companies: URGN Earnings PBYI Earnings MRNS Earnings SPRO Earnings RAPT Earnings NRIX Earnings RLAY Earnings CALT Earnings TARS Earnings XNCR Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:AKBA) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersJoin Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading ...Monument Traders Alliance | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts